Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis


Lanini, S; Molloy, AC; Fine, PE; Prentice, AG; Ippolito, G; Kibbler, CC; (2011) Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. Bmc Medicine, 9. ISSN 1741-7015 DOI: 10.1186/1741-7015-9-36

[img]
Preview
Text - Published Version
License:

Download (2467Kb) | Preview

Abstract

Background: The addition of Rituximab (R) to standard chemotherapy (C) has been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML). Nevertheless, given the profound and prolonged immunosuppression produced by R there are concerns that severe infections may arise. A systematic review and meta-analysis were performed to determine whether or not the addition of R to C may increase the risk of severe infections in adults undergoing induction therapy for CD20+ ML. Methods: Only randomised controlled trials comparing R-C to C standard alone in adult patients with CD20+ ML were included. Meta-analysis was performed on overall incidence of severe infection, risk of dying as the consequence of infection, risk of febrile neutropenia, risk of severe leucopenia, risk of severe granulocytopenia and overall response assuming a fixed effect model. Heterogeneity was investigated, if present and I-2 >20%, according to several predefined baseline characteristics of the study populations. Results: Several relevant results have emerged. First, the addition of R to standard C does not increase the overall risk of severe infections (RR = 1.00; 95% CI 0.87 to 1.14) nor does it increase the risk of dying as a consequence of infection (RR = 1.60; 95% CI 0.68 to 3.75). Second, we confirmed that the addition of R to standard C increases the proportion of overall response (RR = 1.12; 95% CI 1.09 to 1.15), but it also increases the risk of severe leucopenia (RR = 1.24; 95% CI 1.12 to 1.37) and granulocytopenia (RR = 1.07; 95% CI 1.02 to 1.12). Conclusions: R-C is superior to standard C in terms of overall response and it does not increase the overall incidence of severe infection. However, data on special groups of patients (for example, HIV positive subjects and HBV carriers) are lacking. In our opinion more studies are needed to explore the potential effect of R on silent and chronic viral infections.

Item Type: Article
Keywords: NON-HODGKINS-LYMPHOMA, B-VIRUS REACTIVATION, HEPATITIS-B, FOLLICULAR, LYMPHOMA, CELL LYMPHOMA, ENTEROVIRAL MENINGOENCEPHALITIS, RANDOMIZED-TRIALS, PRISMA STATEMENT, VIRAL-INFECTIONS, SURFACE-ANTIGEN
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID: 21481281
Web of Science ID: 290569100001
URI: http://researchonline.lshtm.ac.uk/id/eprint/701

Statistics


Download activity - last 12 months
Downloads since deposit
180Downloads
324Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item